Furet P, Meyer T, Mittl P, Fretz H
Novartis Pharma Inc., Oncology Research Department, Basel, Switzerland.
J Comput Aided Mol Des. 2001 May;15(5):489-95. doi: 10.1023/a:1011128510728.
We have selected cyclin-dependent kinase 1 (CDK1), an enzyme participating in the regulation of the cell cycle, as a target in our efforts to discover new antitumor agents. By exploiting available structural information, we designed an ATP-site directed ligand scaffold that allowed us to identify 4-(3-methyl-1,4-dioxo-1,4-dihydro-naphthalen-2-ylamino)-benzenesulfonamide as a new potent inhibitor of CDK1 in a subsequent database search. The synthesis and testing of some analogues confirmed the interest of this class of compounds as novel CDK1 inhibitors.
我们选择了细胞周期蛋白依赖性激酶1(CDK1),一种参与细胞周期调控的酶,作为我们发现新型抗肿瘤药物的靶点。通过利用现有的结构信息,我们设计了一种ATP位点导向的配体支架,这使我们能够在随后的数据库搜索中确定4-(3-甲基-1,4-二氧代-1,4-二氢萘-2-基氨基)-苯磺酰胺为一种新的强效CDK1抑制剂。一些类似物的合成和测试证实了这类化合物作为新型CDK1抑制剂的价值。